{"entity":{"id":"nct07362836","kind":"trial","name":"Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)","aka":[],"tldr":"A phase 3 trial of fruquintinib and bevacizumab (glioblastoma use) in colorectal cancer, run by Fudan University, not yet recruiting.","summary":"Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS) is a phase 3, randomised interventional study registered as NCT07362836 by Fudan University, with a registry enrolment figure of 224 participants, started 2026-01-31 and due to reach its primary completion in 2028-12-30. Interventions recorded: fruquintinib+chemotherapy; bevacizumab+chemotherapy. Conditions listed: Colorectal Cancer. Primary outcome: Progression-Free Survival. Colorectal eligibility wording from the registry: \"Histologically and/or cytologically confirmed unresectable metastatic colorectal cancer\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07362836","url":"https://clinicaltrials.gov/study/NCT07362836"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["fruquintinib","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07362836","phase":"3","setting":"Fruquintinib Versus Bevacizumab Plus Chemotherapy as Second-Line Therapy for Patients With RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS): A Multicenter Randomized Controlled Trial","sponsor":"Fudan University","enrolled":224,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07362836/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}